About Adicet Bio
Adicet Bio is a company based in Menlo Park (United States) founded in 2014.. Adicet Bio has raised $51 million across 5 funding rounds from investors including Regeneron Pharmaceuticals, HHS and Handok. The company has 152 employees as of December 31, 2024. Adicet Bio has completed 1 acquisition, including Applied Immune Technologies. Adicet Bio operates in a competitive market with competitors including Poseida Therapeutics, Juno Therapeutics, TScan Therapeutics, Lyell Immunopharma and Autolus, among others.
- Headquarter Menlo Park, United States
- Employees 152 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Adicet Bio, Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-117.12 M17.9as on Dec 31, 2024
-
EBITDA
$-121.15 M4.21as on Dec 31, 2024
-
Total Equity Funding
$51 M (USD)
in 5 rounds
-
Latest Funding Round
$15 M (USD), Post-IPO
Feb 16, 2021
-
Investors
Regeneron Pharmaceuticals
& 13 more
-
Employee Count
152
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Adicet Bio
Adicet Bio is a publicly listed company on the NASDAQ with ticker symbol ACET in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Unlock access to complete
Unlock access to complete
Leadership Team
23 people
Software Development Team
9 people
Senior Team
8 people
Scientific Team
6 people
Scientist Team
5 people
Product Management Team
4 people
Human Resources and Administration
4 people
Finance and Accounting
3 people
Unlock access to complete
Funding Insights of Adicet Bio
Adicet Bio has successfully raised a total of $51M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $15 million completed in February 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Post-IPO — $15.0M
-
First Round
First Round
(27 Jan 2016)
- Investors Count 14
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2021 | Amount | Post-IPO - Adicet Bio | Valuation |
investors |
|
| Oct, 2019 | Amount | Post-IPO - Adicet Bio | Valuation | aMoon , Regeneron Pharmaceuticals | |
| May, 2019 | Amount | Grant - Adicet Bio | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Adicet Bio
Adicet Bio has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Regeneron Pharmaceuticals, HHS and Handok. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments in healthcare are focused on by aMoon.
|
Founded Year | Domain | Location | |
|
Venture capital investments are made in promising startups.
|
Founded Year | Domain | Location | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Adicet Bio
Adicet Bio has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Applied Immune Technologies. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
TCRL antibodies are developed for therapeutic and diagnostic applications.
|
2006 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Adicet Bio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Adicet Bio Comparisons
Competitors of Adicet Bio
Adicet Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Poseida Therapeutics, Juno Therapeutics, TScan Therapeutics, Lyell Immunopharma and Autolus, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| domain | founded_year | HQ Location |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| domain | founded_year | HQ Location |
CAR-T and TIL immunotherapies for solid tumors are developed.
|
|
| domain | founded_year | HQ Location |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases.
|
|
| domain | founded_year | HQ Location |
Developer of CAAR T cells for B cell-mediated autoimmune diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Adicet Bio
Frequently Asked Questions about Adicet Bio
When was Adicet Bio founded?
Adicet Bio was founded in 2014 and raised its 1st funding round 2 years after it was founded.
Where is Adicet Bio located?
Adicet Bio is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Who is the current CEO of Adicet Bio?
Anil Singhal is the current CEO of Adicet Bio.
Is Adicet Bio a funded company?
Adicet Bio is a funded company, having raised a total of $51M across 5 funding rounds to date. The company's 1st funding round was a Grant of $2.19M, raised on Jan 27, 2016.
How many employees does Adicet Bio have?
As of Dec 31, 2024, the latest employee count at Adicet Bio is 152.
What does Adicet Bio do?
Adicet Bio was founded in 2014 and is headquartered in Menlo Park, United States. Operations focus on biotechnology, with immune cell therapeutic solutions developed for cancer and immune diseases. Universal immune cell therapies remain in pre-clinical stages, including ADI-001 targeting CD20 for lymphoma, ADI-002 targeting GPC3, and ADI-00x for solid tumors. Leadership is provided by CEO Anil Singhal.
Who are the top competitors of Adicet Bio?
Adicet Bio's top competitors include Juno Therapeutics, Lyell Immunopharma and Immatics.
Is Adicet Bio publicly traded?
Yes, Adicet Bio is publicly traded on NASDAQ under the ticker symbol ACET.
How many acquisitions has Adicet Bio made?
Adicet Bio has made 1 acquisition, including Applied Immune Technologies.
Who are Adicet Bio's investors?
Adicet Bio has 14 investors. Key investors include Regeneron Pharmaceuticals, HHS, Handok, Orbimed, and Samsung Venture Investment.
What is Adicet Bio's ticker symbol?
The ticker symbol of Adicet Bio is ACET on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.